Catamaran Bio: Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies
To develop and manufacture Catamaran Bio's allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.
Read full article »
Catamaran Bio is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer.
Read more